Pharma Mar Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Pharma Mar şirketinin toplam hissedar öz sermayesi €182.2M ve toplam borcu €50.8M olup, bu da borç-öz sermaye oranını 27.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla €333.1M ve €151.0M dir.
Anahtar bilgiler
27.9%
Borç/özkaynak oranı
€50.84m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | €144.39m |
| Eşitlik | €182.17m |
| Toplam yükümlülükler | €150.96m |
| Toplam varlıklar | €333.13m |
Son finansal sağlık güncellemeleri
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Recent updates
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: PHM 'nin kısa vadeli varlıkları ( €238.0M ) kısa vadeli yükümlülüklerini ( €89.4M ) aşıyor.
Uzun Vadeli Yükümlülükler: PHM şirketinin kısa vadeli varlıkları ( €238.0M ) uzun vadeli yükümlülüklerini ( €61.5M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: PHM şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: PHM şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.
Borç Kapsamı: PHM 'nin borcu işletme nakit akışı ( 3.2% ) tarafından iyi bir şekilde karşılanmıyor.
Faiz Kapsamı: PHM şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.